| LENSAR Reports First Quarter 2025 Results and Provides Business Update |
14 ALLY Robotic Laser Cataract Systems™ (“ALLY Systems”) placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 |
globenewswire.com |
2025-05-08 11:00:00 |
Czytaj oryginał (ang.) |
| LENSAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of LENSAR, Inc. - LNSR |
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of LENSAR, Inc. (NasdaqCM: LNSR) to Alcon Inc. (NYSE: ALC). Under the terms of the proposed transaction, shareholders of LENSAR will receive $14.00 in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, for each. |
businesswire.com |
2025-03-26 15:20:00 |
Czytaj oryginał (ang.) |
| ALC Stock Rises Following the Merger Agreement With LENSAR |
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system. |
zacks.com |
2025-03-25 11:36:09 |
Czytaj oryginał (ang.) |
| $HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of LENSAR, Inc. - LNSR |
NEW YORK , March 24, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating LENSAR, Inc. (NASDAQ: LNSR ), relating to the proposed merger with Alcon. |
prnewswire.com |
2025-03-24 12:55:00 |
Czytaj oryginał (ang.) |
| Shareholder Alert: The Ademi Firm Investigates Whether LENSAR, Inc. is Obtaining a Fair Price for Its Public Shareholders |
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating LENSAR (NASDAQ: LNSR) for possible breaches of fiduciary duty and other violations of law in its transaction with Alcon. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, LENSAR shareholders will receive only $14.00 per share in cash (an aggregate implied value of approximately $3. |
businesswire.com |
2025-03-24 11:46:00 |
Czytaj oryginał (ang.) |
| LNSR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of LENSAR, Inc. Is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of LENSAR, Inc. (NASDAQ: LNSR) to Alcon for $14.00 per share in cash, with an additional non-tradeable contingent value right offering up to $2.75 per share in cash conditioned on achievement of a milestone, is fair to LENSAR shareholders. Halper Sadeh encourages LENSAR shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper. |
businesswire.com |
2025-03-24 11:13:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla., March 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 1,600 shares of the Company's common stock. The options were granted as of March 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-03-03 21:03:00 |
Czytaj oryginał (ang.) |
| LENSAR, Inc. (LNSR) Q4 2024 Earnings Call Transcript |
LENSAR, Inc. (NASDAQ:LNSR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning and thank you for your participation. At this time, all participants are in listen-only mode. |
seekingalpha.com |
2025-02-28 15:05:16 |
Czytaj oryginał (ang.) |
| LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update |
31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided an update on key operational initiatives. |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| LENSAR to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 27, 2025 |
ORLANDO, Fla., Feb. 19, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's fourth quarter and full year 2024 financial results will be released before market open on Thursday, February 27, 2025. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, February 27, 2025 to discuss the financial results and recent corporate highlights. |
globenewswire.com |
2025-02-19 14:00:00 |
Czytaj oryginał (ang.) |
| Medical Devices Firm Lensar Surges Ahead On Robotic Technology |
LENSAR, Inc. is rated a Strong Buy by the Quant system, Wall Street analysts, and me, due to its innovative cataract treatment technology and growing market share. The company's ALLY Robotic Cataract Laser System has driven significant revenue and earnings growth, with a one-year price target of $15.15, a 42.21% increase. Despite competition from larger firms, LENSAR's disruptive technology, expanding market share, and strong management team position it well for long-term growth. |
seekingalpha.com |
2025-02-05 06:36:25 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of February 3, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-02-03 21:33:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,650 shares of the Company's common stock. The options were granted as of January 2, 2025, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2025-01-02 20:08:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla., Dec. 09, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted four newly-hired non-executive employees stock options to purchase an aggregate of 2,475 shares of the Company's common stock. The options were granted as of December 8, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-12-09 18:01:00 |
Czytaj oryginał (ang.) |
| LENSAR to Participate in the BTIG 4th Annual Ophthalmology Day |
ORLANDO, Fla., Nov. 26, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced Nick Curtis, Chief Executive Officer, will participate in a fireside chat at the BTIG 4th Annual Ophthalmology Day on Monday, December 2, 2024 at 2 p.m. ET. Additionally, LENSAR management will host 1-on-1 meetings with institutional investors. |
globenewswire.com |
2024-11-26 10:00:00 |
Czytaj oryginał (ang.) |
| LENSAR, Inc. (LNSR) Q3 2024 Earnings Call Transcript |
LENSAR, Inc. (NASDAQ:LNSR ) Q3 2024 Earnings Conference Call November 7, 2024 8:30 AM ET Company Participants Cameron Radinovic - Investor Relations, Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Good morning, and thank you for participation. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-11-09 03:16:54 |
Czytaj oryginał (ang.) |
| LENSAR Reports Third Quarter 2024 Results and Provides Business Update |
24 ALLY Robotic Laser Cataract Systems™ placed in 3Q 2024 including 11 sales in EU and Southeast Asia; Robust backlog with 24 systems pending installation as of September 30, 2024 |
globenewswire.com |
2024-11-07 09:00:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 650 shares of the Company's common stock. The options were granted as of November 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-11-01 20:32:00 |
Czytaj oryginał (ang.) |
| LENSAR to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024 |
ORLANDO, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that the Company's third quarter 2024 financial results will be released before market open on Thursday, November 7, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, November 7, 2024 to discuss the financial results and recent corporate highlights. |
globenewswire.com |
2024-10-31 09:00:00 |
Czytaj oryginał (ang.) |
| One Millionth Procedure Completed Using LENSAR's Cataract Laser Systems |
ORLANDO, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced that more than one million procedures have been performed using its technology. |
globenewswire.com |
2024-10-08 12:00:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of October 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
globenewswire.com |
2024-10-01 22:25:00 |
Czytaj oryginał (ang.) |
| LENSAR, Inc. (LNSR) Q2 2024 Earnings Call Transcript |
LENSAR, Inc. (NASDAQ:LNSR ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Cameron Radinovic - IR Nicholas Curtis - CEO & Director Thomas Staab - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. [Operator Instructions]. |
seekingalpha.com |
2024-08-10 04:15:30 |
Czytaj oryginał (ang.) |
| 3 Under-$10 Stocks With the Potential to Make You a Millionaire |
Buying low-priced stocks with explosive potential is any investor's dream — but it's not easy. Many stocks trade under $10 in the market, yet not all are quality picks. |
investorplace.com |
2024-07-05 14:00:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 2,150 shares of the Company's common stock. The options were granted as of June 3, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listi. |
businesswire.com |
2024-06-03 22:34:00 |
Czytaj oryginał (ang.) |
| LENSAR to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Leerink Partners Healthcare Crossroads Conference on Wednesday, May 29, 2024, at 1:40 p.m. CT in Austin, TX. The live and archived webcast can be accessed through the Investors section of. |
businesswire.com |
2024-05-23 12:00:00 |
Czytaj oryginał (ang.) |
| LENSAR, Inc. (LNSR) Q1 2024 Earnings Call Transcript |
LENSAR, Inc. (NASDAQ:LNSR ) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Lee Roth - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Ryan Zimmerman - BTIG Operator Good morning, and thank you for your participation. At this time, all participants are in a listen-only mode. |
seekingalpha.com |
2024-05-11 19:50:09 |
Czytaj oryginał (ang.) |
| LENSAR to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024 |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company's first quarter 2024 financial results will be released before market open on Thursday, May 9, 2024. LENSAR's management will host a conference call and webcast at 8:30 am ET on Thursday, May 9, 2024 to discuss the financial results and recent corporate highlig. |
businesswire.com |
2024-05-02 12:00:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted two newly-hired non-executive employees stock options to purchase an aggregate of 875 shares of the Company's common stock. The options were granted as of May 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq Listing Ru. |
businesswire.com |
2024-05-01 22:38:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”) today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees stock options to purchase an aggregate of 1,425 shares of the Company's common stock. The options were granted as of April 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq List. |
businesswire.com |
2024-04-01 22:28:00 |
Czytaj oryginał (ang.) |
| LENSAR, Inc. (LNSR) Q4 2023 Earnings Call Transcript |
LENSAR, Inc. (NASDAQ:LNSR ) Q4 2023 Earnings Conference Call March 4, 2024 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - Chief Executive Officer Thomas Staab - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Operator Good morning and thank you for your participation. At this time all participants are in a listen-only mode. |
seekingalpha.com |
2024-03-04 12:36:08 |
Czytaj oryginał (ang.) |
| LENSAR Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced financial results for the quarter and full year ended December 31, 2023 and provided an update on key operational initiatives. “Our strong performance throughout 2023 continued in the fourth quarter, resulting in total revenue up 18% over the fourth quarter of 2022, with full-y. |
businesswire.com |
2024-03-04 09:00:00 |
Czytaj oryginał (ang.) |
| LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
ORLANDO, Fla.--(BUSINESS WIRE)--LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”) today announced that a majority of the independent members of LENSAR's board of directors granted seven newly-hired non-executive employees stock options to purchase an aggregate of 4,175 shares of the Company's common stock. The options were granted as of March 1, 2024, as inducements material to each employee entering into employment with the Company. The options were granted in accordance with Nasdaq List. |
businesswire.com |
2024-03-01 19:01:00 |
Czytaj oryginał (ang.) |